The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
Open accessAbstract
Adeno-associated virus (AAV)–mediated gene transfer of factor IX (F.IX) to the liver results in long-term expression of transgene in experimental animals, but only short-term expression in humans. Loss of F.IX expression is likely due to a cytotoxic immune response to the AAV capsid, which results in clearance of transduced hepatocytes. We used a nonhuman primate model to assess the safety of AAV gene transfer coupled with an anti–T-cell regimen designed to block this immune response. Administration of a 3-drug regimen consisting of mycophenolate mofetil (MMF), sirolimus, and the anti–IL-2 receptor antibody daclizumab consistently resulted in formation of inhibitory antibodies to human F.IX following hepatic artery administration of an AAV-hF.IX vector, whereas a 2-drug regimen consisting only of MMF and sirolimus did not. Administration of daclizumab was accompanied by a dramatic drop in the population of CD4+CD25+FoxP3+ regulatory T cells (Tregs). We conclude that choice of immunosuppression (IS) regimen can modulate immune responses to the transgene product upon hepatic gene transfer in subjects not fully tolerant; and that induction of transgene tolerance may depend on a population of antigen-specific Tregs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies suggest that following secondary AAV exposure, capsid-specific memory T cells produce cytokines and acquire a cytotoxic phenotype [27, 106–108].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [107]
In the citing paper
“However, systemic IS may increase the risk of infection and is not effective in complete remission of high titer NAbs [107, 169].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [107]
In the citing paper
“Despite the wide application, systemic immune suppression may cause Treg suppression and multiple adverse effects, including intestinal complications, muscle pain ,and headaches, which has brought other strategies to light [107, 226–228].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [107]
In the citing paper
“Pre-clinical studies have applied immunosuppression as an alternative to control anti-capsid cellular immune response (42–44).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [43]
In the citing paper
“and may also deplete Tregs.66”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [66]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationRapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Battaglia, M., Stabilini, A., & Roncarolo, M.-G. (2005) · Blood · doi:10.1182/blood-2004-10-3932 · Cited by 1,134
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationBattaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T., & Roncarolo, M.-G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8338 · Cited by 736
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
Self-citationBlockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339 · cited 1×
“We chose to use NHP for these studies for the following reasons: (1) there is considerable experience with IS drugs28-30 and with AAV vector infusion31-33 in NHP, so the baseline toxicities for both types of agents are well-described in these animals; (2) IS drugs such as daclizumab (the humanized anti–IL-2 receptor a…”
MethodSelf-citationJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Self-citationHaemophilia B: database of point mutations and short additions and deletions--second edition
Giannelli, F., Green, P. M., High, K. A., Sommer, S., Lillicrap, D. P., Ludwig, M., Olek, K., Reitsma, P. H., Goossens, M., Yoshioka, A., et al. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.suppl.2193 · Cited by 298
Self-citation
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“High vector doses may trigger anticapsid CTL responses 4,15,95,128 ; Relatively low-titer antibodies (1:5-1:17) can neutralize large doses of vector.”
Self-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationAntigen-presenting cell function in the tolerogenic liver environment
Thomson, A. W., & Knolle, P. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2858 · Cited by 805
“Interestingly, hepatic T Reg cells seem to be required for prolonged transgene expression in hepatocytes in a non-human primate mode”
BackgroundImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
Metadata
- Authors
- Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., Arruda, V. R., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Division of Hematology and Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, PA;
- Avigen, Alameda, CA
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-10-01
- Volume
- 110
- Issue
- 7
- Pages
- 2334-2341
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC1988950
- OpenAlex
- W2048487684
- Cited by
- 254
- References
- 43
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 9 · 2023: 17 · 2022: 9 · 2021: 17 · 2020: 15 · 2019: 18 · 2018: 9 · 2017: 16 · 2016: 3 · 2015: 6 · 2014: 12 · 2013: 17 · 2012: 12
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (NIH T32, HL07439)
- National Heart, Lung, and Blood Institute (R01HL084220, T32 HL07439, P01HL078810, T32HL007439, T32HL007150)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV gene delivery, factor IX, hemophilia B, immune tolerance induction, regulatory T cells, immunosuppression, daclizumab, mycophenolate mofetil, rapamycin, anti-IL-2 receptor antibody, hepatocyte clearance, liver gene transfer, nonhuman primate model
- MeSH terms
- Daclizumab, Adenoviridae, Animals, Antibodies, Monoclonal, B-Lymphocytes, Factor IX, Genetic Vectors, Humans, Immunoglobulin G, Immune Tolerance, Immunosuppressive Agents, Liver, Macaca mulatta, Male, Mycophenolic Acid, Genetic Therapy, Receptors, Interleukin-2, CD4-Positive T-Lymphocytes, Gene Expression, Gene Transfer Techniques, Transgenes, Sirolimus, Models, Animal, Capsid Proteins, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. https://app.cochat.ai/papers/10.1182/blood-2007-03-080093
- The paper
- Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., Arruda, V. R., & High, K. A. (2007). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. https://doi.org/10.1182/blood-2007-03-080093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.